SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records containing laboratory data generated in the course of the Program to enable it to furnish complete and accurate information to OGS regarding the Program activities and results, including all Preliminary Compounds, Active Compounds and NeoMorph Focused Libraries identified in the Program and all Program Intellectual Property developed during the Program. All such written records of NeoGenesis shall be open to inspection by OGS during normal business hours upon reasonable prior written notice. (b) NeoGenesis shall provide OGS with reasonably-detailed written reports describing the results of the research performed pursuant to the Program including all Preliminary Compounds, Active Compounds and NeoMorph Focused Libraries identified in the Program. Such reports shall be delivered to OGS at least monthly during the Program. NeoGenesis will deliver a Final Target Report (as defined in ATTACHMENT A) with respect to the Program work performed on each Target including a description of all the Preliminary Compounds, Primary Active Compounds and NeoMorph Sublibraries identified during the Program with respect to such Target.
Appears in 2 contracts
Sources: Screening and Analysis Services Agreement (Neogenesis Pharmaceuticals Inc), Confidential Treatment Agreement (Neogenesis Pharmaceuticals Inc)
SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records containing laboratory data generated in the course of the Program to enable it to furnish complete and accurate information to OGS Mitsubishi regarding the Program activities and results, including all Preliminary CompoundsCandidate Compound A, Active Compounds Candidate Compound B and NeoMorph Focused Libraries identified in the Program and all Program Intellectual Property developed by NeoGenesis during the Program. All such written records of NeoGenesis shall be open to inspection by OGS Mitsubishi during normal business hours upon reasonable prior written notice.
(b) NeoGenesis shall provide OGS Mitsubishi with reasonably-detailed written reports describing the results of the research performed pursuant to the Program including all Preliminary CompoundsCandidate Compound A, Active Compounds Candidate Compound B and NeoMorph Focused Libraries identified in the Program. Such reports shall be delivered to OGS Mitsubishi at least monthly during the Program. NeoGenesis will deliver a Final Target Report (as defined in ATTACHMENT A) with respect to the Program work performed on each Target including a description of all the Preliminary CompoundsCandidate Compound A, Primary Active Compounds Candidate Compound B and NeoMorph Sublibraries identified during the Program with respect to such Target.
Appears in 2 contracts
Sources: Confidentiality Agreement (Neogenesis Pharmaceuticals Inc), Service Agreement (Neogenesis Pharmaceuticals Inc)
SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records containing laboratory data generated in the course of the Program to enable it to furnish complete and accurate information to OGS regarding the Program activities and results, including all Preliminary Compounds, Active Compounds and NeoMorph Focused Libraries identified in the Program and all Program Intellectual Property developed during the Program. All such written records of NeoGenesis shall be open to inspection by OGS during normal business hours upon reasonable prior written notice.
(b) NeoGenesis shall provide OGS with reasonably-detailed written reports describing the results of the research performed pursuant to the Program including all Preliminary Compounds, Active Compounds and NeoMorph Focused Libraries identified in the Program. Such reports shall be delivered to OGS at least monthly during the Program. NeoGenesis will deliver a Final Target Report (as defined in ATTACHMENT Attachment A) with respect to the Program work performed on each Target including a description of all the Preliminary Compounds, Primary Active Compounds and NeoMorph Sublibraries identified during the Program with respect to such Target.
Appears in 1 contract
Sources: License Agreement (Iaso Pharma Inc)